Formyl Peptide Receptor-1 Blockade Prevents Receptor Regulation by Mitochondrial Danger-Associated Molecular Patterns and Preserves Neutrophil Function After Trauma.
Journal
Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
25
8
2020
Statut:
ppublish
Résumé
Trauma predisposes to systemic sterile inflammation (systemic inflammatory response syndrome) as well as infection, but the mechanisms linking injury to infection are poorly understood. Mitochondrial debris contains formyl peptides. These bind formyl peptide receptor-1, trafficking neutrophils to wounds, initiating systemic inflammatory response syndrome, and wound healing. Bacterial formyl peptides, however, also attract neutrophils via formyl peptide receptor-1. Thus, mitochondrial formyl peptides might suppress neutrophils antimicrobial function. Also, formyl peptide receptor-1 blockade used to mitigate systemic inflammatory response syndrome might predispose to sepsis. We examined how mitochondrial formyl peptides impact neutrophils functions contributing to antimicrobial responses and how formyl peptide receptor-1 antagonists affect those functions. Prospective study of human and murine neutrophils and clinical cohort analysis. University research laboratory and level 1 trauma center. Trauma patients, volunteer controls. C57Bl/6, formyl peptide receptor-1, and formyl peptide receptor-2 knockout mice. Human and murine neutrophils functions were activated with autologous mitochondrial debris, mitochondrial formyl peptides, or bacterial formyl peptides followed by chemokines or leukotrienes. The experiments were repeated using formyl peptide receptor-1 antagonist cyclosporin H, "designer" human formyl peptide receptor-1 antagonists (POL7178 and POL7200), or anti-formyl peptide receptor-1 antibodies. Mouse injury/lung infection model was used to evaluate effect of formyl peptide receptor-1 inhibition. Human neutrophils cytosolic calcium, chemotaxis, reactive oxygen species production, and phagocytosis were studied before and after exposure to mitochondrial debris, mitochondrial formyl peptides, and bacterial formyl peptides. Mitochondrial formyl peptide and bacterial formyl peptides had similar effects on neutrophils. Responses to chemokines and leukotrienes were suppressed by prior exposure to formyl peptides. POL7200 and POL7178 were specific antagonists of human formyl peptide receptor-1 and more effective than cyclosporin H or anti-formyl peptide receptor-1 antibodies. Formyl peptides inhibited mouse neutrophils responses to chemokines only if formyl peptide receptor-1 was present. Formyl peptide receptor-1 blockade did not inhibit neutrophils bacterial phagocytosis or reactive oxygen species production. Cyclosporin H increased bacterial clearance in lungs after injury. Formyl peptides both activate and desensitize neutrophils. Formyl peptide receptor-1 blockade prevents desensitization, potentially both diminishing systemic inflammatory response syndrome and protecting the host against secondary infection after tissue trauma or primary infection.
Identifiants
pubmed: 31939811
doi: 10.1097/CCM.0000000000004094
pii: 00003246-202002000-00032
pmc: PMC7337247
mid: NIHMS1550528
doi:
Substances chimiques
FPR1 protein, human
0
Mitochondrial Proteins
0
Receptors, Formyl Peptide
0
Cyclosporine
83HN0GTJ6D
cyclosporin H
FUO6O3NDNH
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e123-e132Subventions
Organisme : NIAID NIH HHS
ID : R03 AI135346
Pays : United States
Références
Nature. 1981 Sep 24;293(5830):302-5
pubmed: 7196996
J Trauma Acute Care Surg. 2018 Nov;85(5):936-943
pubmed: 29787548
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16278-83
pubmed: 18852457
Methods Mol Biol. 2012;844:115-24
pubmed: 22262438
J Biol Chem. 1989 Jun 15;264(17):9939-44
pubmed: 2656716
J Immunol. 2006 Sep 1;177(5):3201-8
pubmed: 16920959
Am J Pathol. 2015 May;185(5):1172-84
pubmed: 25791526
Thorax. 2017 Oct;72(10):928-936
pubmed: 28469031
Nature. 2010 Mar 4;464(7285):104-7
pubmed: 20203610
Am J Respir Cell Mol Biol. 1993 Jul;9(1):73-81
pubmed: 8393326
Immunity. 2010 Aug 27;33(2):148-9
pubmed: 20732637
J Trauma Acute Care Surg. 2014 May;76(5):1222-7
pubmed: 24747452
J Trauma Acute Care Surg. 2015 Feb;78(2):272-9; discussion 279-81
pubmed: 25757111
Immunol Rev. 2019 May;289(1):205-231
pubmed: 30977203
Molecules. 2017 Mar 13;22(3):
pubmed: 28335409
J Trauma. 1974 Mar;14(3):187-96
pubmed: 4814394
J Immunol. 2003 Aug 15;171(4):2066-73
pubmed: 12902512
J Biol Chem. 1985 Mar 25;260(6):3440-50
pubmed: 3838314
Curr Protoc Immunol. 2015 Aug 03;110:3.20.1-3.20.15
pubmed: 26237011
J Infect Dis. 1991 Apr;163(4):837-42
pubmed: 1849163
Sci Rep. 2017 Jul 19;7(1):5918
pubmed: 28724995
J Trauma. 1990 Dec;30(12 Suppl):S80-5
pubmed: 2254997
J Biol Chem. 1997 Jun 13;272(24):15213-9
pubmed: 9182544
J Immunol Res. 2017;2017:1254792
pubmed: 29164154
J Trauma Acute Care Surg. 2017 May;82(5):853-860
pubmed: 28431414
J Lipid Res. 2010 May;51(5):1075-84
pubmed: 19965602
J Trauma. 2010 Jun;68(6):1328-32; discussion 1332-4
pubmed: 20539176
J Immunol. 2002 Apr 15;168(8):4063-9
pubmed: 11937565
J Biochem. 2015 Feb;157(2):65-71
pubmed: 25480980